MCKESSON CORPORATION Federal Contracts — Government Award History

Total (All Time)$43.8B
Recent FY$8.2B
Top Agency

MCKESSON CORPORATION has received $43.8B in total federal contract awards.
Primary awarding agency: .

Data source: USASpending.gov

Awards by Fiscal Year

Year Total Contracts Top Agency
FY2026 $8216.8M 7
FY2025 $11449.6M 12
FY2024 $8608.3M 12
FY2023 $9215.9M 12
FY2022 $6312.5M 9

Recent Contracts

Date Agency Amount Description
2025-11-01 $1406.9M EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 NOVEMBER
2026-04-01 $1191.3M EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 APRIL
2025-10-01 $1184.2M EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 OCTOBER
2025-09-01 $1177.9M EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2025 SEPTEMBER
2026-03-01 $1175.7M EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 MARCH
2025-07-01 $1118.0M EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2025 JULY
2025-12-01 $1110.4M EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 DECEMBER
2026-01-01 $1088.0M EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 JANUARY
2025-08-01 $1075.4M EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2025 AUGUST
2026-02-01 $1060.3M EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 FEBRUARY
2024-10-01 $1048.0M EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2025 OCTOBER
2025-04-01 $1045.9M EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2025 APRIL
2025-05-01 $1043.5M EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2025 MAY
2025-06-01 $1020.3M EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2025 JUNE
2025-03-01 $1000.0M EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2025 MARCH
2024-07-01 $971.8M EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2024 JULY
2024-09-01 $953.2M EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2024 SEPTEMBER
2024-08-01 $943.8M EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2024 AUGUST
2024-11-01 $912.0M EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2025 NOVEMBER
2023-09-01 $902.0M EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2023 SEPTEMBER